NEW YORK, July 16, 2021 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an
update to the progress of its antiviral platform with the
University of Maryland School of
Medicine. The Company stated:
The goal for the project is the identification and optimization
of anti-viral compounds that inhibit viral replication by targeting
a protein complex that degrades RNA at the cellular level.
Scientists have identified proteins that are required for viral
replication in these viruses. Computers were also used to aid
the drug design approach by identifying compounds that are
predicted to block viral replication. From this work,
scientists have identified 4 lead compounds that block Influenza,
Coronavirus (CoV-2), and Ebolavirus replication.
Anthony Hayes, CEO of AIkido
Pharma stated, "Moving forward, the upcoming phase is to optimize
the best of these compounds to make them even better. At the
same time, the scientists will take the compounds and measure how
well they are bioavailable in the lungs when given either as an
injection or as an oral dosing. Ultimately the goal is to
have compounds that demonstrate strong antiviral activity against
Influenza virus, SARS-CoV-2, and Ebolavirus. These illnesses
have significant unmet medical needs as demonstrated by their
continued resurgence and represent tremendous market
About AIkido Pharma Inc.
AIkido Pharma Inc. was
initially formed in 1967 and is a biotechnology Company with a
diverse portfolio of small-molecule anti-cancer therapeutics.
The Company's platform consists of patented technology from leading
universities and researchers, and we are currently in the process
of developing an innovative therapeutic drug platform through
strong partnerships with world renowned educational institutions,
including The University of Texas at Austin and University of
Maryland at Baltimore. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer and prostate
cancer. We are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology. The Company is also
developing a broad-spectrum antiviral platform that may potentially
inhibit replication of multiple viruses including Influenza virus,
SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Certain statements in this
press release constitute "forward-looking statements" within the
meaning of the federal securities laws. Words such as "may,"
"might," "will," "should," "believe," "expect," "anticipate,"
"estimate," "continue," "predict," "forecast," "project," "plan,"
"intend" or similar expressions, or statements regarding intent,
belief, or current expectations, are forward-looking statements.
While the Company believes these forward-looking statements are
reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are based upon current estimates and assumptions and are
subject to various risks and uncertainties, including without
limitation those set forth in the Company's filings with the SEC,
not limited to Risk Factors relating to its business contained
therein. Thus, actual results could be materially different. The
Company expressly disclaims any obligation to update or alter
statements whether as a result of new information, future events or
otherwise, except as required by law.
Brett Maas, Managing Partner
Phone: (646) 536-7331
AIkido Pharma Inc.:
View original content to download
SOURCE AIkido Pharma Inc.